Less than a tenth of individuals eligible to benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it issues its inaugural advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our new guidelines recognises that obesity is a lifelong illness that can be managed with holistic and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major hurdles to universal access to the injections that can assist patients in reducing substantial weight, notes the agency.
Weight-Loss Drug Scarcity
Despite the current most optimistic outlook, the supply of such drugs would only suffice for around 100 million people – under 10% of eligible patients, per the health organization.
The guideline encourages countries and companies to widen access, via approaches like patent sharing.
A patent on a key compound – the core component of a leading brand – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Injections Work
The injections imitate a body's own hormone to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals eat less.
People typically see weight reduction in the initial weeks of commencing the regular doses.
Studies indicates users may put most of the weight back on within a year of stopping the medication, because their usual appetite come back.
Being overweight or obese elevates your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and some malignancies.
Obesity impacts people in every country and was associated with millions of deaths worldwide in 2024, as per the health agency.
